In parallel with mRNA assays, Western blot results showed that FGFR1 and PARP1 protein expression levels were 1.55- and 1.84-fold higher, respectively, in poorly differentiated FGFRi-resistant primary tumor PANC-1 cells than FGFRi-sensitive metastatic SUIT-2 cells (Figure 1B). Here, PARP1 is linked to neoplasm.